Background: To examine the prospective association between multivitamin supplementation during pregnancy and biomarker measures of maternal plasma folate and vitamin B 12 levels at birth and child's Autism Spectrum Disorder (ASD) risk. Methods: This report included 1257 mother-child pairs, who were recruited at birth and prospectively followed through childhood at the Boston Medical Center. ASD was defined from diagnostic codes in electronic medical records. Maternal multivitamin supplementation was assessed via questionnaire interview; maternal plasma folate and B 12 were measured from samples taken 2-3 days after birth. Results: Moderate (3-5 times/week) self-reported supplementation during pregnancy was associated with decreased risk of ASD, consistent with previous findings. Using this as the reference group, low (≤2 times/week) and high (>5 times/week) supplementation was associated with increased risk of ASD. Very high levels of maternal plasma folate at birth (≥60.3 nmol/L) had 2.5 times increased risk of ASD [95% confidence interval (CI) 1.3, 4.6] compared to folate levels in the middle 80th percentile, after adjusting for covariates including MTHFR genotype. Similarly, very high B 12 (≥536.8 pmol/L) showed 2.5 times increased risk (95% CI 1.4, 4.5). Conclusion: There was a 'U shaped' relationship between maternal multivitamin supplementation frequency and ASD risk. Extremely high maternal plasma folate and B 12 levels at birth were associated with ASD risk. This hypothesis-generating study does not question the importance of consuming adequate folic acid and vitamin B 12 during pregnancy; rather, raises new questions about the impact of extremely elevated levels of plasma folate and B 12 exposure in-utero on early brain development.
stantial evidence that folic acid supplementation reduces the risk of neural tube defects (NTD) in offspring, the US Public Health Service recommended in 1992 that women of reproductive age consume 400 lg/d before and during pregnancy. Subsequently, mandatory fortification of cereal grain products at a suggested level of 140 lg folic acid/100 g was implemented in the US in 1998. 9 In the post-fortification era, serum folate levels in the US have increased 2.5 times across all life stages, including among pregnant women. 10 A recent NHANES study showed that unmetabolized folic acid (either from folic acid supplementation or fortified grain products) has been detected in most of the U.S. population. 11 Furthermore, data from the Boston Birth
Cohort showed a wide range of individual variation in plasma folate levels ranging from insufficient to excessive levels. 12 The association between folic acid intake during pregnancy and ASD risk in offspring has been equivocal. Several studies suggest that mothers who use a periconceptional multivitamin or folic acid supplementation are less likely to have offspring with ASD, 2,13 yet, others have hypothesized an opposite relationship. [14] [15] [16] Preliminary studies that included both women's report of prenatal vitamin use and maternal biomarker data found a protective effect of prenatal vitamins intake on ASD based on report, but this relationship could not be confirmed using biomarker data. 17, 18 Given this background, in this hypothesis-generating study, we evaluated the relationship between self-reported pregnancy multivitamin intake, and plasma folate levels in mothers at birth and ASD in offspring. Since both vitamin B 12 and folate are intricately involved in one-carbon metabolism and there are very few studies on B 12 status on human brain, 19 we also explored the association between maternal B 12 biomarker levels and ASD risk in offspring.
Methods

Participants and data collection procedure
The study included mother-infant pairs who were recruited at the Boston Medical Center (BMC) at the time of birth from 1998 to 2013 and followed up prospectively from 2003 to 2015 ( Figure S1 ), as described elsewhere. 12, 20 Children who were not intending to receive paediatric care at the BMC were excluded. Mothers who had a post-birth blood sample for analysing plasma folate and B 12 and who had data on maternal multivitamin supplement intake during at least the third trimester were included in the analysis.
Mothers of newborns were approached 24-72 h postpartum to participate in the study. After obtaining informed consent, a standard questionnaire was used to collect relevant maternal data including supplement intake. Maternal and infant medical records were reviewed using standardized abstraction forms to collect data on pre-pregnancy weight and pregnancy related complications. Maternal blood samples collected 24-72 h post-delivery were later analysed for maternal plasma folate, B 12 and homocysteine levels. Children were followed from birth through both study visits and clinical paediatric visits at the BMC. Electronic Medical Records (EMR) containing clinicians' primary and secondary diagnoses using ICD-9 codes were obtained for every postnatal clinical visit starting in 2003. The study was approved by the Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health and Boston University Medical Center.
Identification of children with ASD
Based on EMR, children who were ever diagnosed with autism (ICD-9 code 299.00), Asperger syndrome (299.80) and/or pervasive developmental disorder not otherwise specified (299.90) were categorized as having ASD, as described elsewhere. 21 Children who concomitantly had ASD and ADHD, ASD and other developmental disabilities, or ASD and intellectual disabilities were classified as having ASD. Children without ASD, ADHD (314.0-314.9), other developmental (315.0-315.9), or intellectual disabilities (317-319) constituted the 'neurotypical' group. Children diagnosed with ADHD or other developmental or intellectual disabilities without concurrent ASD were excluded from the analysis. One subject who had Ventricular Septal Defect (VSD), but was miscoded as having ASD, was identified and excluded. For sensitivity analyses, children with ASD were restricted to those with an ASD code for at least two visits and where at least one visit was with a specialist (developmental behavioural paediatrician, paediatric neurologist, or child psychologist). Sensitivity analyses were also implemented restricting neurotypical children to only those that did not have other competing diagnoses, including congenital anomalies and psychiatric or behavioural disorders (see Table S1 ).
Exposures
Plasma folate was measured using chemiluminescent immunoassay with diagnostic kits (Shenzhen New Industries Biomedical Engineering Co., Ltd. China) and plasma B 12 was measured using the Beckman Coulter ACCESS Immunoassay System (BeckmanCoulter Canada, Mississauga, Canada) using a MAGLUMI 2000 Analyzer. The interassay coefficient of variation was less than 4%. 12 Mothers with the lowest and highest deciles (top and bottom 10th percentiles) of the plasma folate (<14.7 and ≥60.3 nmol/ L) and B 12 (<247.0 and ≥536.8 pmol/L) distributions were compared against the middle 80th percentile. Preconception multivitamin intake was dichotomized (no vs. yes) and prenatal multivitamin supplement intake was coded as a categorical variable (supplement ≤2 times/week, 3-5 times/week and >5 times/week). Mothers ever diagnosed with diabetes (250.00-250.93) were identified as pre-gestational diabetes cases and those ever diagnosed with diabetes mellitus complicating pregnancy (648.00 and 648.03) comprised gestational diabetes cases.
Covariates
Plasma homocysteine levels were measured using automatic clinical analyzers (Beckman-Coulter). Homocysteine was considered as a binary variable with the top 10th percentile of the distribution compared against the bottom 90th percentile (<11.7 lmol/ L). Other covariates were chosen a priori based on previous studies looking at maternal nutritional status and the risk of ASD. 13, 22 Neonates who were delivered at or after 37 completed weeks of gestation were considered full term; those delivered <34 weeks, and ≥34 but <37 weeks of gestation were considered early and late preterm, respectively. Race-ethnicity was categorized into black, white, Hispanic and Other. Other covariates assessed were: child sex (female vs. male), maternal age at delivery, smoking during pregnancy ('ever smoked' 3 months before pregnancy/during pregnancy vs. 'no smoking' during preconception/ pregnancy), parity (not including the index pregnancy), maternal education (high school or less vs.
some college or more), year of the baby's birth (1998-2006 vs. 2007-2013) , and Methylene tetrahydrofolate reductase (MTHFR) C677T genotypes (CC vs. CT vs. TT).
Statistical analyses
The primary outcome variable was ASD and exposures were maternal vitamin supplementation during preconception, first, second, and third trimesters or maternal plasma folate and B 12 levels in the days after birth. Preliminary data analysis was performed to compare neurotypical children and those with ASD using chi-squared tests for categorical variables and ANOVA for continuous variables. We fitted a Cox proportional hazard regression model to estimate hazard ratios and account for the variability in length of follow-up. Birth of the child was defined as the time of origin and the child's first postnatal visit recorded in the EMR was defined as the time of entry. The child exited the ASD risk pool if he/she had the event (ASD diagnosis) or was censored after his/her recorded last postnatal visit. In addition, the role of maternal MTHFR C677T genotype was examined via stratification and cross-product proportional hazard regression analyses. We tested the interaction of maternal folate (as a binary variable) and 1) B 12 levels (as a binary variable) and 2) MTHFR C677T (as a categorical variable) on the risk of ASD.
Results
A total of 1257 mother-infant pairs were included in the analysis, of which 86 were ASD cases and 1171 were children with neurotypical development (Figure S1 ). Children with ASD had co-morbidities including ADHD (n = 25), intellectual disabilities (n = 39) and other developmental disabilities (n = 76), that were not mutually exclusive. Table 1 describes the characteristics of mothers and children in each group. The frequency of multivitamin supplement intake during third trimester differed between mothers whose children had ASD when compared to those who had children with neurotypical development. They were also more likely to have higher pre-pregnancy BMI, pre-gestational/gestational diabetes and very high maternal B 12 (≥90th percentile). The distribution of folate and B 12 levels in our study population is consistent with the NHANES data for women of reproductive age ( Figure S2 ) and detailed comparisons are provided in Tables S2 and S3 . To understand the impact of differential follow-up, analyses were conducted on this cohort comparing baseline characteristics of the children included in the analyses and those excluded from the analyses. Maternal multivitamin supplement intake preconception was not statistically significantly associated with the risk of ASD in children ( Table 2) . Consistent with previous research, 13 first trimester supplement intake (≥ 3 times/week) was protective against ASD risk when compared to those who reported taking a supplement <3 times/week; or conversely, low levels of multivitamin supplement intake were associated with increased ASD risk. When supplement intake was stratified by intake frequency, a 'U shaped' relationship was observed, with maternal supplement intake ≤2 times/week and >5 times/week during both demonstrating statistically significantly increased risk for ASD (Table 2 and Figure 1 ). This 'U shaped' relationship was consistent across all trimesters and became stronger after adjusting for potential confounders. Elevated maternal plasma B 12 (>600 pmol/L) compared to non-elevated (≥200-≤600 pmol/L) levels was associated with increase in risk of ASD in offspring in both unadjusted and adjusted models (Table 3) . 23 Deficient B 12 (<200 pmol/L) compared to normal levels was not associated with ASD risk (Table 3) .
The risk of ASD in children along the continuum of plasma folate and B 12 is presented in Figure 2 and Tables S4 and S5 . Using the WHO suggested threshold, the risk of ASD was not significantly different between children when their mothers had possibly deficient (<13.5 nmol/L) or excess (>45.3 nmol/L) plasma folate levels after birth, compared to mothers who had normal levels (≥13.5 to ≤45.3) (Table 3) . However, the risk of ASD among mother-child pairs with higher levels of plasma folate suggests association at increasing folate levels. We categorized and compared the lowest and highest deciles with the middle 80th percentiles for maternal folate (<14.7 and ≥60.3 nmol/L) and B 12 levels (<247.0 and ≥536.8 pmol/L). Mothers with plasma folate levels in the highest 10th percentile, when compared with the middle 80th percentile, had a significant increase in the risk of children's ASD in both unadjusted and adjusted models (Table 3) . Mothers who had plasma folate levels in the lowest decile did not have increased ASD risk in children in the adjusted model (Table 3) . Plasma B 12 levels in the top decile, when compared to the middle 80%, was associated with about two and half times increased risk (Table 3) . However, the risk of ASD in children whose mothers had lowest levels of plasma B 12 was not significantly different than the referent group in both models. Similarly, elevated maternal plasma homocysteine when compared to non-elevated levels did not alter ASD risk even after accounting for confounders (Table 3) .
We compared self-reported maternal multivitamin supplement intake to measured biomarker levels after birth. Nearly all mothers took supplements during pregnancy; the frequencies of use for first, second, and third trimesters were 86.2%, 90.2%, and 89.1% respectively. Within each supplement intake category, there was a range in maternal plasma folate and B 12 levels (Table S6 , Figures S3 and S4 ). There were no differences in the mean plasma folate levels between non-supplement users and different levels of supplement users, except those who had supplements 3-5 times/week. The percentage of mothers with elevated plasma folate and B 12 did not vary between different levels of supplement intake. When supplement intake was stratified by parity, a greater percentage of nulliparous women were likely to consume supplements >5 times/week in the first and third trimesters (Table S7) .
We assessed the joint effects of maternal plasma folate and B 12 levels on the risk of ASD in children by considering mothers who had both biomarkers in the middle 80th percentile at delivery as the referent category (Table 3 ). The risk of ASD in children was not different between mothers with only one or the other biomarker in an extreme decile compared to mothers who had both biomarkers in the middle 80th percentile, after adjusting for confounders. For mothers who had at least one biomarker level (plasma folate and/or B 12 ) in the lowest decile, the risk of ASD in children was not different, nor was it for both in the lowest decile (Table 3) . Mothers who had at least one or both biomarkers in the top decile did have an increased risk for ASD in their offspring in adjusted models (Table 3 ). There was an interaction between maternal folate and B 12 (P < 0.01). MTHFR genotype was available for 96.5% of the mothers (n = 1213) of which 794 (65.9%), 347 (28.6%), and 72 (5.9%) had CC, CT, and TT genotype respectively. In this sample, maternal MTHFR genotype did not differ between children with neurotypical development and those with ASD (Table S8 ). No differences in genotype were observed by maternal folate and B 12 levels (Table S9 ). The geometric means of plasma folate were also not significantly different across different genotypes (Table S10 ) and there was no interaction between maternal folate and MTHFR genotype status on ASD risk.
To assess the influence of EMR misclassification of ASD or neurotypical development on these findings, a sensitivity analysis (Table S11 ) was conducted applying stringent criteria for case diagnosis (ASD code for at least two visits, including a specialist) and for children with neurotypical development (excluding potential developmental disability indications) ( Table S1 ). The results demonstrate slightly stronger associations in this smaller sample; mothers who had plasma folate in the top decile had more than twofold greater ASD risk (HR 2.4, 95% CI 1.1, 5.0) and with plasma B 12 in the top decile had almost four times increased risk (HR 3.9, 95% CI 2.0, 7.7), after adjusting 
Comment
Principal findings
The results show that moderate intake (3-5 times/ week) of multivitamin supplements during pregnancy is associated with decreased risk of ASD in offspring, consistent with the previous literature. 2, 13 Upon further examination of the risk at the low and high ends of intake, the study results further suggest that while infrequent intake (≤2 times/week) of multivitamin supplements is associated with increased risk of ASD, as has been reported previously, high frequency of multivitamin supplement intake (>5 times/week) is also associated with increased risk of ASD in children in this cohort, compared to moderate intake. This is the first study to report on the prospective association between measured maternal plasma folate and B 12 biomarkers at birth and risk of ASD in offspring in a large, prospective US birth cohort. Consistent with the 'U-shaped' finding for supplement intake, the biomarker analyses showed that very high levels of maternal plasma folate and B 12 (≥90th percentile) at birth were also associated with increased risk of ASD in offspring.
With regard to post-delivery biomarkers, which are reasonably consistent with third trimester pregnancy levels, 24, 25 maternal plasma folate and B 12 in the highest decile (≥90th percentile) were each associated with increased risk of ASD in children. A moderate level of self-reported supplement intake (3-5 times/week) is protective against ASD, but that an increased risk is observed with higher and lower intake of multivitamin supplements, and with very high concentrations of plasma folate (≥90th percentile) and B 12 (≥90th percentile) biomarkers at birth. This observation suggests that while deficiency is detrimental, excess nutrient status might also be associated with elevated risk.
Interpretation
For over a century, it has been known that the doseresponse relationship for many micronutrients is nonmonotonic: at low levels benefits increase with intake until plateauing at optimal concentrations, with toxicity at higher levels, as regulatory mechanisms become overwhelmed. 26, 27 In a landmark paper, Daly et al.
showed that maximum NTD risk was observed in mothers who had folate deficiency (0-4.4 nmol/L).
There was a dose-response relationship with risk plateauing beyond maternal folate levels of 11.3 nmol/L and no apparent additional benefits beyond levels of 15.9 nmol/L. 28 At the other end of the spectrum, this study observed an increased ASD risk when mothers had plasma folate levels in the top decile during the third trimester (corresponding to The unadjusted HR for plasma folate (panel a) was truncated at 65 nmol/ L due to the small sample size beyond the specified cutoff point (unadjusted HR for mothers whose plasma folate ≥65 nmol/L was 1.9, 95% CI 1.0, 3.4; n = 113). The unadjusted HR for plasma vitamin B 12 (panel B) was truncated at 700 pmol/L due to declining sample sizes beyond the specified cutoff point (unadjusted HR for mothers whose plasma vitamin B 12 ≥700 pmol/L was 2.8, 95% CI 1.3, 6.0; n = 45).
60.3 nmol/L), which is well beyond the highest level recommended by WHO (45.3 nmol/L). This study is not able to directly attribute the source of these high levels for the top decile. It is possible that adverse birth outcomes, such as NTD, spontaneous abortions, stillbirths, and developmental disabilities, 29, 30, 31 in a previous delivery might have prompted some pregnant women to consume higher dosages of prenatal vitamins, which could explain elevated biomarker levels. However, there were no significant difference in previous adverse pregnancy outcomes between mothers with ASD and children with neurotypical development in this sample. Upon further examination of EMR-based medication history for mothers of children with ASD, none of them were prescribed megadoses of prenatal vitamins. Mandatory folic acid fortification was instituted in the U.S. in January 1998 and the BBC began enrolling mothers in October 1998. Considering that BBC is a post-fortification study, it is possible that women with high folic acid intake also consumed folic acid from multiple sources including fortified foods, possibly creating an accumulation of folic acid, as observed in a recent NHANES study. 32 In this sample, mothers who consumed more supplements were also more likely to have consumed fortified foods (e.g. pasta, bread, cereal), suggesting that the combination of dietary folic acid along with supplement intake might have potentially resulted in elevated levels, although correlations between supplement intake and biomarker levels were not extremely high. This study notes that the highest ASD risk (HR 13.7, 95% CI 6.5, 28.9) was observed in children of mothers with both plasma folate and B 12 elevated (≥90th percentile). In addition, a significant interaction was observed between plasma folate and B 12 (P < 0.001) suggesting possible perturbation in one-carbon metabolism, which intimately involves both micronutrients.
One possible theory suggests that elevated maternal folate levels in the past few decades have altered natural selection, increasing the survival rates of those with the MTHFR C677T polymorphism by reducing miscarriage rates. 15 It is also possible that genetic variation may interfere with folic acid absorption or metabolism to folate precluding the benefits of folic acid and promoting accumulation in maternal blood. In this study, there was no relationship between the MTHFR C677T variant, plasma folate, and ASD risk. However, the study did not exhaustively examine variation in this gene, or other genes in the one-carbon cycle. Also, due to the small number of mothers with TT genotype in this sample, the study might be underpowered to address this question. It is not surprising that some nutrients are tightly regulated within a narrow range, given that both deficiency and excess can induce abnormal brain development. 33 The concentration of nutrients can have an impact on the brain development with a nutrient that promotes normal development in one concentration may be toxic at another. 33 Similarly, the timing of supplementation or deficiency can also have a role to play in brain function. 33, 34 Pregnant women have superior absorption of folic acid and B 12 compared to non-pregnant counterparts 35 and excrete minimal folate in urine during the third trimester 36 -all of which could have lead to increased plasma levels. Considering the elevated maternal levels in addition to fetus's ability to actively absorb micronutrients, it is likely that some offspring may have accumulated high levels of these micronutrients. The fetal brain is vulnerable to nutritional insults especially during the third trimester, when several neurological processes including synaptogenesis increase in cortical volume and cortical connectivity between different regions, myelination, and pruning are occurring at a rapid rate. 33, [37] [38] [39] [40] Human and animal studies have shown that suboptimal intake of folic acid during pregnancy can induce persistent changes in the offspring's genome, thereby influencing physiological outcomes. [41] [42] [43] [44] [45] With regards to neurocognitive development, increase in maternal folate during gestation in animal models alters gene expression in cerebral and cerebellar hemispheres. 41, 42 Specifically, key developmental genes involved in neural pathways, gamma-Aminobutyic acid (GABA), dopamine-serotonin, and synaptic plasticity demonstrated altered expression and impairment in many of the pathways are linked to ASD. 42, 46, 47 Prolonged exposure to high folic acid has been shown to alter offspring's behaviour, including greater anxiety-like behaviour, ultrasonic vocalizations in pups (linked to autism in mouse models), and hyperactivity. 42 B 12 plays an important role in DNA methylation, in addition to being integrally involved in myelination, 48 cellular growth, and differentiation. 49 Yet, there is a dearth of research on the role of B 12 status on developing brains. 19 A cross-sectional study showed that maternal B 12 measured at parturition was inversely associated with DNA methylation of insulin-like growth factor (IGF-2) in cord blood. Limitations and strengths of the study Case and neurotypical development classification was based on the EMR, rather than using adjudication based on the research-reliable gold standard diagnostic assessments such as the Autism Diagnostic Interview-Revised (ADI-R) or the Autism Diagnostic Observation Schedule (ADOS). 51 This approach enables consideration of all children with available administrative data, but may misclassify some children as ASD who have other developmental or behavioural problems. The study findings were consistent even when restricting cases to those with multiple visits indicating an ASD diagnostic code, including by a specialist. Further, if such misclassification of atypical, but non-ASD children exists in the sample, the results would imply that elevated maternal plasma folate and B 12 levels could have implications in other developmental disabilities beyond ASD. Maternal dietary intake data during preconception and pregnancy might have provided additional perspectives on the study results and lack of this information is a limitation. Maternal plasma folate and B 12 were measured 24-72 h after delivery; this may reflect maternal folate and B 12 levels only during the third trimester and may not reflect early pregnancy status. Despite plasma folate being a marker of recent intake and more susceptible to variations in diet, it is well correlated with red blood cell folate and thus is a reliable marker. 52 Although we had information on the frequency of maternal multivitamin supplement intake, lack of information on the specific dosage is a limitation. A study based on the NHANES data suggests that a majority of pregnant women consume ≥800 lg of folic acid when using supplements and we assume this to be true of women in this cohort as well. 53 We adjusted for well-recognized ASD risk factors, but there is a possibility of residual confounding. Finally, the study population consists mainly of urban low-income minority women and extrapolation of study findings to other populations should be made with caution. While the study suggests that very low or very high maternal folate and B 12 measured at delivery may be associated with ASD in offspring, further research in the following areas will be beneficial, beginning with replication of these findings in independent cohorts with more vigorous ASD phenotyping, understanding the mechanism connecting elevated folate, B 12 to neurocognitive development and examining the source of elevated biomarkers. Further, more research is needed to understand if the window of exposure affects the impact of folic acid supplementation.
Conclusion
The aetiology of ASD is complex and this study provides a new perspective but not a definitive explanation. This hypothesis-generating study does not question the importance of consuming adequate amounts of folic acid and B 12 during pregnancy; the results confirm the protective effects of adequate vitamin supplementation for ASD risk, as observed in previous studies. Rather, it raises questions about whether excessive amounts of maternal folate and B 12 may be harmful if a 'U-shaped' risk curve is confirmed, as has been observed for other health-related risk. 54 This result suggests further investigation of this potentially 'U-shaped' risk in other cohorts and underscores the critical importance of identifying optimum maternal levels of folate and B 12 for fetal/ child neurodevelopment.
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